KKR-backed Biosynth Carbosynth Acquires vivitide; Ampersand Rolls Over Stake
March 17, 2022
KKR has invested in Biosynth Carbosynth through its Health Care Strategic Growth Fund II, and Biosynth Carbosynth has acquired vivitide, a global provider of custom peptides and antibody services. Existing owner Ampersand Capital Partners rolled over its entire stake and will be a substantial minority shareholder in the combined global life‑sciences reagents and custom synthesis platform to accelerate geographic expansion, broaden capabilities, and expand the product portfolio.
- Buyers
- Biosynth Carbosynth, KKR
- Targets
- vivitide
- Platforms
- Biosynth Carbosynth
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.